Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.57% | 19.95% | -1.66% | -21.21% | -47.86% |
| Total Depreciation and Amortization | 6.32% | 4.79% | 3.85% | 4.62% | 6.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.33% | -43.31% | -29.03% | -4.09% | 44.88% |
| Change in Net Operating Assets | -368.74% | -475.20% | -448.66% | -273.59% | 28.35% |
| Cash from Operations | 7.05% | -11.35% | -21.45% | -59.88% | -51.02% |
| Capital Expenditure | -73.30% | -45.95% | 17.46% | 28.34% | 59.70% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.96% | 0.04% | 4.00% | -628,738.46% | -185,692.06% |
| Cash from Investing | 78.72% | -0.14% | 4.07% | -14,387.83% | -21,732.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.38% | -7.61% | -30.00% | -20.30% | -28.61% |
| Issuance of Common Stock | 126.63% | 3,329.11% | 145.13% | -58.96% | -59.00% |
| Repurchase of Common Stock | -- | -- | -- | 69.23% | 69.23% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.78% | -166.82% | -166.42% | -8.72% | -8.54% |
| Cash from Financing | 134.44% | 164,739.10% | 144.20% | -61.40% | -62.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.11% | 125.79% | 132.37% | -195.44% | -207.77% |